Akari Therapeutics (AKTX) Non-Current Assets (2012 - 2026)
Akari Therapeutics (AKTX) posted quarterly Non-Current Assets of $30.3 million for Q1 2026, down 36.36% year-on-year from $47.6 million in Q1 2025, and down 28.59% on a QoQ basis from $42.4 million in Q4 2025.
Akari Therapeutics (AKTX) Non-Current Assets (2012 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has reported Non-Current Assets for 14 consecutive years, with $30.3 million the latest figure, recorded in Q1 2026.
- Quarterly Non-Current Assets fell 36.36% year-over-year to $30.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $162.8 million (up 70.94% YoY) and the FY2025 annual result came in at $42.4 million, down 10.88% from the prior year.
- Non-Current Assets fell to $30.3 million in Q1 2026 per AKTX's latest filing, from $42.4 million in the prior quarter.
- Over the last five years, Non-Current Assets for AKTX reached as high as $47.6 million in Q4 2024 and fell as low as $14000.0 in Q4 2023.
- A 5-year average of $25.8 million and a median of $36.4 million in 2025 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2024 — Non-Current Assets surged 339971.43% — and 2026, when it slumped 36.36%.
- Year by year, Non-Current Assets stood at $17000.0 in 2022, then dropped by 17.65% to $14000.0 in 2023, then jumped by 339971.43% to $47.6 million in 2024, then dropped by 10.88% to $42.4 million in 2025, then slipped by 28.59% to $30.3 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $30.3 million, $42.4 million, and $42.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Akari Therapeutics | 86.55 Mn | 86.55 Mn | - | 30.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.30 Mn |
| Dec 31, 2025 | 42.43 Mn |
| Sep 30, 2025 | 42.43 Mn |
| Jun 30, 2025 | 47.61 Mn |
| Mar 31, 2025 | 47.61 Mn |
| Dec 31, 2024 | 47.61 Mn |
| Dec 31, 2023 | 14,000.00 |
| Jun 30, 2023 | 15,779.00 |
| Dec 31, 2022 | 17,000.00 |
| Jun 30, 2022 | 18,844.00 |
| Dec 31, 2021 | 22,929.00 |
| Jun 30, 2021 | 25,546.00 |
| Dec 31, 2020 | 27,150.00 |
| Sep 30, 2020 | 26,674.00 |
| Jun 30, 2020 | 26,489.00 |
| Mar 31, 2020 | 29,662.00 |
| Dec 31, 2019 | 35,176.00 |
| Sep 30, 2019 | 37,535.00 |
| Jun 30, 2019 | 60,485.00 |
| Mar 31, 2019 | 196,625.00 |